CN116473997B - Hypochlorous acid disinfectant and preparation method thereof - Google Patents
Hypochlorous acid disinfectant and preparation method thereof Download PDFInfo
- Publication number
- CN116473997B CN116473997B CN202310736606.0A CN202310736606A CN116473997B CN 116473997 B CN116473997 B CN 116473997B CN 202310736606 A CN202310736606 A CN 202310736606A CN 116473997 B CN116473997 B CN 116473997B
- Authority
- CN
- China
- Prior art keywords
- parts
- hypochlorous acid
- disinfectant
- antibiotic
- polysaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 title claims abstract description 65
- 239000000645 desinfectant Substances 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 230000003115 biocidal effect Effects 0.000 claims abstract description 54
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 35
- 239000005017 polysaccharide Substances 0.000 claims abstract description 35
- 150000004676 glycans Chemical class 0.000 claims abstract description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 28
- 150000001875 compounds Chemical class 0.000 claims abstract description 25
- 239000008367 deionised water Substances 0.000 claims abstract description 25
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 25
- 239000003381 stabilizer Substances 0.000 claims abstract description 20
- 239000004094 surface-active agent Substances 0.000 claims abstract description 20
- BBFCIBZLAVOLCF-UHFFFAOYSA-N pyridin-1-ium;bromide Chemical compound Br.C1=CC=NC=C1 BBFCIBZLAVOLCF-UHFFFAOYSA-N 0.000 claims abstract description 18
- 238000003756 stirring Methods 0.000 claims description 37
- 229920001661 Chitosan Polymers 0.000 claims description 28
- 229920002678 cellulose Polymers 0.000 claims description 22
- 239000001913 cellulose Substances 0.000 claims description 22
- 239000007864 aqueous solution Substances 0.000 claims description 17
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 17
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 17
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 17
- 239000000243 solution Substances 0.000 claims description 17
- 238000000502 dialysis Methods 0.000 claims description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- -1 polyoxyethylene Polymers 0.000 claims description 15
- 239000007809 chemical reaction catalyst Substances 0.000 claims description 14
- 238000003411 electrode reaction Methods 0.000 claims description 14
- 239000011248 coating agent Substances 0.000 claims description 12
- 238000000576 coating method Methods 0.000 claims description 12
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 10
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- 239000002041 carbon nanotube Substances 0.000 claims description 8
- 229910021393 carbon nanotube Inorganic materials 0.000 claims description 8
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 6
- 230000006196 deacetylation Effects 0.000 claims description 6
- 238000003381 deacetylation reaction Methods 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 5
- 229920000875 Dissolving pulp Polymers 0.000 claims description 5
- IGFHQQFPSIBGKE-UHFFFAOYSA-N Nonylphenol Natural products CCCCCCCCCC1=CC=C(O)C=C1 IGFHQQFPSIBGKE-UHFFFAOYSA-N 0.000 claims description 5
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 5
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 claims description 5
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 claims description 5
- 238000004945 emulsification Methods 0.000 claims description 5
- 150000002191 fatty alcohols Chemical class 0.000 claims description 5
- 239000000787 lecithin Substances 0.000 claims description 5
- 235000010445 lecithin Nutrition 0.000 claims description 5
- 229940067606 lecithin Drugs 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Chemical compound CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 claims description 5
- 229940051841 polyoxyethylene ether Drugs 0.000 claims description 5
- 229920000056 polyoxyethylene ether Polymers 0.000 claims description 5
- 239000001103 potassium chloride Substances 0.000 claims description 5
- 235000011164 potassium chloride Nutrition 0.000 claims description 5
- ZIWRUEGECALFST-UHFFFAOYSA-M sodium 4-(4-dodecoxysulfonylphenoxy)benzenesulfonate Chemical compound [Na+].CCCCCCCCCCCCOS(=O)(=O)c1ccc(Oc2ccc(cc2)S([O-])(=O)=O)cc1 ZIWRUEGECALFST-UHFFFAOYSA-M 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 claims description 5
- 235000019982 sodium hexametaphosphate Nutrition 0.000 claims description 5
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims description 5
- 235000019345 sodium thiosulphate Nutrition 0.000 claims description 5
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 claims description 5
- 238000009210 therapy by ultrasound Methods 0.000 claims description 5
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 claims description 5
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 3
- 229930191564 Monensin Natural products 0.000 claims description 3
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 claims description 3
- 239000004115 Sodium Silicate Substances 0.000 claims description 3
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 3
- 229960005358 monensin Drugs 0.000 claims description 3
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 claims description 3
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 claims description 3
- 239000001488 sodium phosphate Substances 0.000 claims description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 3
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 claims description 3
- 229910052911 sodium silicate Inorganic materials 0.000 claims description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 3
- 239000004098 Tetracycline Substances 0.000 claims description 2
- 108010059993 Vancomycin Proteins 0.000 claims description 2
- 229960002180 tetracycline Drugs 0.000 claims description 2
- 229930101283 tetracycline Natural products 0.000 claims description 2
- 235000019364 tetracycline Nutrition 0.000 claims description 2
- 150000003522 tetracyclines Chemical class 0.000 claims description 2
- 229960003165 vancomycin Drugs 0.000 claims description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims 1
- 238000011012 sanitization Methods 0.000 claims 1
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 21
- 230000001954 sterilising effect Effects 0.000 abstract description 18
- 210000003491 skin Anatomy 0.000 abstract description 16
- 241000894006 Bacteria Species 0.000 abstract description 12
- 239000003814 drug Substances 0.000 abstract description 12
- 206010052428 Wound Diseases 0.000 abstract description 11
- 208000027418 Wounds and injury Diseases 0.000 abstract description 11
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract description 9
- 239000000460 chlorine Substances 0.000 abstract description 9
- 229910052801 chlorine Inorganic materials 0.000 abstract description 9
- 244000052769 pathogen Species 0.000 abstract description 9
- 210000004207 dermis Anatomy 0.000 abstract description 8
- 239000002674 ointment Substances 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 208000017520 skin disease Diseases 0.000 abstract description 6
- 231100000245 skin permeability Toxicity 0.000 abstract description 5
- 230000003628 erosive effect Effects 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 206010072170 Skin wound Diseases 0.000 abstract description 3
- 230000000638 stimulation Effects 0.000 abstract description 2
- 239000003242 anti bacterial agent Substances 0.000 description 15
- 229940088710 antibiotic agent Drugs 0.000 description 15
- 230000000844 anti-bacterial effect Effects 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000003385 bacteriostatic effect Effects 0.000 description 7
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- 241001052560 Thallis Species 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 208000035404 Autolysis Diseases 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 206010057248 Cell death Diseases 0.000 description 3
- 102000004310 Ion Channels Human genes 0.000 description 3
- 206010040840 Skin erosion Diseases 0.000 description 3
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 3
- HPMVBVNXFPHBLR-UHFFFAOYSA-N [Br-].[NH4+].C(CCCCCCCCCCCCC)C=1C(=NC=CC1)C Chemical compound [Br-].[NH4+].C(CCCCCCCCCCCCC)C=1C(=NC=CC1)C HPMVBVNXFPHBLR-UHFFFAOYSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000005265 energy consumption Methods 0.000 description 3
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Inorganic materials Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000028043 self proteolysis Effects 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000005868 electrolysis reaction Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- GBDGHHBEUZVCBC-UHFFFAOYSA-N [Br-].[NH4+].C(CCCCCCCCCCCCCCC)C1=NC=CC=C1 Chemical compound [Br-].[NH4+].C(CCCCCCCCCCCCCCC)C1=NC=CC=C1 GBDGHHBEUZVCBC-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- UQUKAYGSKZWZJY-UHFFFAOYSA-N azanium 2-dodecylpyridine bromide Chemical compound [Br-].[NH4+].C(CCCCCCCCCCC)C1=NC=CC=C1 UQUKAYGSKZWZJY-UHFFFAOYSA-N 0.000 description 1
- GKKSXJDSOAJLQE-UHFFFAOYSA-N azanium;pyridine;bromide Chemical compound [NH4+].[Br-].C1=CC=NC=C1 GKKSXJDSOAJLQE-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical group [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical group O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000007603 infrared drying Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007785 strong electrolyte Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
- A61K31/79—Polymers of vinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
- C25B—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
- C25B1/00—Electrolytic production of inorganic compounds or non-metals
- C25B1/01—Products
- C25B1/24—Halogens or compounds thereof
- C25B1/26—Chlorine; Compounds thereof
-
- C—CHEMISTRY; METALLURGY
- C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
- C25B—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
- C25B11/00—Electrodes; Manufacture thereof not otherwise provided for
- C25B11/04—Electrodes; Manufacture thereof not otherwise provided for characterised by the material
- C25B11/051—Electrodes formed of electrocatalysts on a substrate or carrier
- C25B11/052—Electrodes comprising one or more electrocatalytic coatings on a substrate
-
- C—CHEMISTRY; METALLURGY
- C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
- C25B—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
- C25B11/00—Electrodes; Manufacture thereof not otherwise provided for
- C25B11/04—Electrodes; Manufacture thereof not otherwise provided for characterised by the material
- C25B11/051—Electrodes formed of electrocatalysts on a substrate or carrier
- C25B11/073—Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalyst material
- C25B11/075—Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalyst material consisting of a single catalytic element or catalytic compound
-
- C—CHEMISTRY; METALLURGY
- C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
- C25B—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
- C25B11/00—Electrodes; Manufacture thereof not otherwise provided for
- C25B11/04—Electrodes; Manufacture thereof not otherwise provided for characterised by the material
- C25B11/051—Electrodes formed of electrocatalysts on a substrate or carrier
- C25B11/073—Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalyst material
- C25B11/091—Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalyst material consisting of at least one catalytic element and at least one catalytic compound; consisting of two or more catalytic elements or catalytic compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention discloses hypochlorous acid disinfectant and a preparation method thereof, and relates to the technical field of disinfectant, wherein the disinfectant comprises the following components in parts by weight: 2-6 parts of hypochlorous acid, 10-15 parts of polysaccharide antibiotic compound, 2-6 parts of pyridinium bromide, 4-9 parts of stabilizer, 1-4 parts of neutralizer, 12-17 parts of surfactant and 65-80 parts of deionized water. The concentration of available chlorine in the product is 400-800 ppm, the pH value of the whole solution of the disinfectant is kept 5-6, pyridinium bromide is sterilized by being matched with hypochlorous acid, and the polysaccharide antibiotic component is added, so that the stimulation to wound surfaces of wounds can be reduced, pathogens and bacteria are eliminated, the skin permeability of the ointment is increased, the medicine is permeated into the dermis of the skin to perform treatment and auxiliary hypochlorous acid deep sterilization, the effect of promoting is achieved, and the disinfectant is suitable for sterilizing skin wounds with high erosion degrees such as operation, skin diseases and burn.
Description
Technical Field
The invention relates to the technical field of disinfectant, in particular to hypochlorous acid disinfectant and a preparation method thereof.
Background
Sodium hypochlorite is a strong electrolyte, firstly ionizes in water to generate hypochlorite ions, and if the hypochlorite ions hydrolyze, hypochlorous acid can be generated, the hypochlorite ions are further decomposed to generate nascent oxygen, and the nascent oxygen has very active chemical property and very strong oxidizing power and plays a great role in the disinfection process. The disinfection principle of the hypochlorous acid disinfectant is that hypochlorous acid is subjected to oxidation-reduction action with bacterial cell walls and virus shells to crack germs; because of unstable decomposition to generate nascent oxygen, the extremely strong oxidizing property of the nascent oxygen denatures the proteins of thalli and viruses, thereby killing pathogenic microorganisms; chloride ions can significantly alter the osmotic pressure of bacteria and virions, resulting in their loss of activity and death.
Antibiotics have been the primary drug to treat bacterial infections since the discovery of penicillin in the 40 th century. With the widespread use of antibiotics, drug-resistant strains have become pathogenic bacteria which are common in clinical infections, and the generation and increasing of multi-drug resistance phenomenon make the treatment of bacterial infections very challenging. For infection caused by intracellular bacteria, antibiotics must first bind to target pathogenic bacteria in the cell to act, and thus the antibacterial effect of the antibiotics is affected by many factors, including the concentration, distribution and duration of action of the antibiotics in the cell. Therefore, the method carries out certain chemical modification on the antibiotics, optimizes the intracellular pharmacokinetic parameters of the antibiotics, and has great significance for expanding the application of the existing antibiotics in the treatment of infection caused by intracellular bacteria.
Publication number CN108079017B discloses a hypochlorous acid wound disinfectant containing antibacterial polysaccharide compounds or derivatives, which has good sterilizing effect and long duration, but the product of the invention is only used for superficial wound disinfection, is not suitable for skin wound surfaces with higher erosion degree, has poor skin permeability of medicines, and cannot deeply sterilize and assist in medicine treatment.
Disclosure of Invention
The invention aims to solve the technical problems and needs, and discloses hypochlorous acid disinfectant which is higher in available chlorine content, stronger in sterilization effect, capable of increasing skin permeability of ointment, capable of promoting medicine penetration into dermis of skin for treatment and assisting hypochlorous acid deep sterilization, and suitable for disinfecting skin wounds with higher erosion degrees such as surgery, skin diseases and burns.
The invention adopts the following technical scheme:
the hypochlorous acid disinfectant comprises the following components in parts by weight: 2-6 parts of hypochlorous acid, 10-15 parts of polysaccharide antibiotic compound, 2-6 parts of pyridinium bromide, 5-9 parts of polyvinylpyrrolidone, 4-9 parts of stabilizer, 1-4 parts of neutralizer, 12-17 parts of surfactant and 65-80 parts of deionized water.
Preferably, the disinfectant comprises the following components in parts by weight: 3-5 parts of hypochlorous acid, 11-14 parts of polysaccharide antibiotic compound, 2-4 parts of pyridinium bromide, 6-8 parts of polyvinylpyrrolidone, 6-8 parts of stabilizer, 1-3 parts of neutralizer, 13-16 parts of surfactant and 68-73 parts of deionized water.
Preferably, the disinfectant comprises the following components in parts by weight: 4 parts of hypochlorous acid, 12 parts of polysaccharide antibiotic compound, 3 parts of pyridinium bromide, 7 parts of polyvinylpyrrolidone, 7 parts of stabilizer, 2 parts of neutralizer, 15 parts of surfactant and 70 parts of deionized water.
Preferably, the concentration of available chlorine in the disinfectant is 400-800 ppm, and the pH value of the whole disinfectant solution is kept to be 5-6.
Preferably, the pyridine ammonium bromide is selected from one of cetyl pyridine ammonium bromide, dodecyl pyridine ammonium bromide, tetradecyl-2-methyl pyridine ammonium bromide, n-butyl pyridine ammonium bromide, more preferably tetradecyl-2-methyl pyridine ammonium bromide. The tetradecyl-2-methylpyridine ammonium bromide is an electrolyte, and the external groups can ionize water and can be used in an electrolysis system of a nano material together with polyvinylpyrrolidone.
Preferably, the hypochlorous acid preparation method comprises the following steps:
s1, pretreating an anode of an electrolytic cell, adding a carbon nano tube into propylene glycol, performing ultrasonic treatment for 30 minutes, coating an electrode reaction catalyst on the anode, and roasting at 200-300 ℃ for 30 minutes to finish the treatment;
s2, introducing 0.1-0.2wt% of sodium chloride or potassium chloride solution into the cathode chamber and the anode chamber, connecting with a power supply of an electrolytic tank, and carrying out electrolysis to obtain hypochlorous acid.
Preferably, the electrode reaction catalyst is a mixture of platinum dioxide and tin tetrachloride in a mass ratio of 3:1.
Preferably, the coating amount of the electrode reaction catalyst on the anode is 8-10 g/m 2 。
According to the invention, the anode is coated with the catalyst to form the rugged honeycomb coating on the surface of the anode, so that the number of active points on the surface of the anode is increased, the electrochemical activity of the anode is improved, the carbon nano tube provides attachment points for platinum and tin, finer grains are promoted to be obtained, the hypochlorous acid produced by the electrode under the condition of low energy consumption can release stable high-concentration available chlorine, the sterilization and disinfection capability is stronger, and the synergistic sterilization with the polysaccharide antibiotics is facilitated.
Preferably, the preparation method of the polysaccharide antibiotic complex comprises the following steps:
s11, preparing chitosan and antibiotic aqueous solution, wherein the molar ratio of chitosan to antibiotic to deionized water is (1:3) - (5): 10-15, adding sodium cyanoborohydride accounting for 20-30% of the mass of the antibiotic, stirring at room temperature in a dark place, and reacting at 90-100 ℃ for 8-12 h;
s12, transferring the aqueous solution obtained in the step S11 into a 3kDa dialysis bag for dialysis for 2-3 d to obtain a dialysate;
s13, dissolving cellulose in deionized water with the mass of 2 times that of the cellulose, mixing a cellulose aqueous solution and a dialyzate under a stirring condition, and continuously stirring for 2-3 hours at the temperature of 30-40 ℃;
s14, carrying out vacuum freeze drying on the mixed solution obtained in the step S13 for 36-48 hours, wherein the temperature is-30 to-50 ℃, and the vacuum degree is 20-30 Pa, so as to obtain the polysaccharide antibiotic compound.
Preferably, the molecular weight cut-off of the dialysis bag is 3000-7000.
Preferably, the chitosan is carboxymethyl chitosan with a deacetylation degree of more than 80%;
preferably, the cellulose is hydroxypropyl cellulose or sodium carboxymethyl cellulose;
preferably, the antibiotic is one of vancomycin, tetracycline, la Sha Junsu and monensin.
Preferably, the stabilizer comprises one or more of disodium ethylenediamine tetraacetate, sodium silicate and sodium phosphate.
Preferably, the neutralizer is a PBS solution containing 0.5-1wt% of sodium thiosulfate, 0.5-1wt% of lecithin and 1-2wt% of Tween 60.
The chitosan, cellulose and antibiotic compound is added, so that the antibacterial disinfectant has good biocompatibility and excellent film forming performance, is sprayed on the surface of a severe skin erosion wound when being used for medical disinfectant, acts on pathogen or bacterial cell membranes remained on the dermis layer of the skin to cause perforation and destroy ion channels of the pathogen, finally leads to autolysis and death of thalli, can form an antibacterial and bacteriostatic breathable film on the surface of the skin, has a blocking effect on external bacteria, can reduce the stimulation of hypochlorous acid on the skin, and helps to realize drug permeation treatment.
Preferably, the surfactant comprises by weight: 2-8 parts of fatty alcohol polyoxyethylene ether, 3-7 parts of sodium dodecyl diphenyl ether disulfonate, 1-4 parts of sodium hexametaphosphate, 8-12 parts of alkylphenol polyoxyethylene and 5-10 parts of nonylphenol polyoxyethylene.
Preferably, the preparation method of the disinfectant comprises the following steps:
dissolving pyridinium bromide, polyvinylpyrrolidone and hypochlorous acid in deionized water, adding into a vacuum emulsification stirrer, vacuumizing and stirring for 30min; slowly adding a stabilizer and a neutralizer, stirring while adding, and adjusting the pH value to 5.5-6; and adding the polysaccharide antibiotic compound, stirring for 20-30 min at 30-35 ℃, slowly adding the surfactant, and stirring for 10-20 min to obtain the hypochlorous acid disinfectant.
The hypochlorous acid disinfectant is applied to medical disinfection, and is particularly applied to pre-drug disinfection or daily disinfection of surgical wound surfaces, burn wound surfaces, acne ulcer wound surfaces and various skin disease wound surfaces with higher erosion degree; the skin diseases include, but are not limited to, AIDS, syphilis, herpes zoster or herpes simplex, erythema scale skin diseases, acute suppurative skin diseases caused by fungal or bacterial infections.
The invention has the beneficial effects that:
the hypochlorous acid disinfectant disclosed by the invention uses pyridinium bromide and polyvinylpyrrolidone to be matched with hypochlorous acid for sterilization, so that the duration of the sterilizing effect of the hypochlorous acid on wound surfaces is prolonged.
The disinfectant disclosed by the invention is introduced with chitosan, cellulose and antibiotic compound, can kill pathogens, has an antibacterial effect, good biocompatibility and excellent film forming performance, is sprayed on the surface of a severe skin erosion wound when being used for medical disinfection, acts on the cell membrane of pathogens or bacteria which are retained in the dermis of the skin, causes perforation, damages the ion channel of the pathogens, and finally causes autolysis of thalli to die. The antibacterial and bacteriostatic breathable film can be formed on the surface of the skin, so that the antibacterial and bacteriostatic breathable film has a blocking effect on external bacteria, the skin permeability of the ointment is increased, and the antibacterial and bacteriostatic ointment has a promoting effect on the treatment of drug permeation into the dermis of the skin and the auxiliary hypochlorous acid deep sterilization.
According to the invention, the anode of the electrolytic tank for producing hypochlorous acid is coated with the catalyst, the rugged honeycomb coating is formed on the surface of the anode, the number of active points on the surface of the anode is increased, the electrochemical activity of the anode is improved, the carbon nano tube provides attachment points for platinum and tin, finer grains are promoted to be obtained, the hypochlorous acid produced by the electrode under the condition of low energy consumption can release stable high-concentration available chlorine, the sterilizing capacity is more efficient, and the synergistic sterilization with polysaccharide antibiotics is facilitated.
Detailed Description
The following description of the embodiments of the present invention will be made clearly and fully with reference to the accompanying drawings, in which it is evident that the embodiments described are only some, but not all embodiments of the invention. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Example 1.
The hypochlorous acid disinfectant of the embodiment comprises the following components in parts by weight: 2 parts of hypochlorous acid, 10 parts of polysaccharide antibiotic compound, 2 parts of pyridinium bromide, 5 parts of polyvinylpyrrolidone, 4 parts of stabilizer, 1 part of neutralizer, 12 parts of surfactant and 65 parts of deionized water.
The concentration of available chlorine in the disinfectant of this example was 400ppm, and the pH of the entire solution of the disinfectant was maintained at 5.
The hypochlorous acid preparation method of the embodiment comprises the following steps:
s1, pretreating an anode of an electrolytic cell, adding a carbon nano tube into propylene glycol, performing ultrasonic treatment for 30min, coating an electrode reaction catalyst on the anode, and roasting at 200 ℃ for 30min to finish the treatment;
s2, introducing 0.1wt% of sodium chloride or potassium chloride solution into the cathode chamber and the anode chamber, and connecting with a power supply of an electrolytic tank to electrolyze to obtain hypochlorous acid.
The electrode reaction catalyst of this example was a mixture of platinum dioxide and tin tetrachloride in a mass ratio of 3:1.
The coating amount of the electrode reaction catalyst on the anode of this example was 8g/m 2 。
The preparation method of the polysaccharide antibiotic complex of the embodiment comprises the following steps:
s11, preparing chitosan and antibiotic aqueous solution, wherein the molar ratio of chitosan to antibiotic to deionized water is 1:3:10, adding 20% of cyano sodium borohydride by mass of antibiotics, stirring at room temperature in a dark place, and reacting at 90 ℃ for 8 hours;
s12, transferring the aqueous solution obtained in the step S11 into a 3kDa dialysis bag for dialysis for 2d to obtain dialysate;
s13, dissolving cellulose in deionized water with the mass of 2 times of that of the cellulose, mixing the cellulose aqueous solution and the dialyzate under the stirring condition, and continuously stirring for 2 hours at 30 ℃;
s14, carrying out vacuum freeze drying on the mixed solution obtained in the step S13 for 36 hours, wherein the temperature is-30 ℃ and the vacuum degree is 20Pa, and thus the polysaccharide antibiotic compound is obtained.
The dialysis bag of this example has a molecular weight cut-off of 3000.
The chitosan of the embodiment is carboxymethyl chitosan with the deacetylation degree of more than 80 percent;
the cellulose of this example is hydroxypropyl cellulose;
the antibiotic of this example is vancomycin.
The stabilizer of this example was disodium ethylenediamine tetraacetate.
The neutralizing agent of this example was a PBS solution containing 0.5wt% sodium thiosulfate, 0.5wt% lecithin, and 1wt% Tween 60.
The surfactant of this embodiment comprises, in parts by weight: 2 parts of fatty alcohol polyoxyethylene ether, 3 parts of sodium dodecyl diphenyl ether disulfonate, 1 part of sodium hexametaphosphate, 8 parts of alkylphenol polyoxyethylene and 5 parts of nonylphenol polyoxyethylene.
The preparation method of the disinfectant of the embodiment comprises the following steps:
dissolving pyridinium bromide, polyvinylpyrrolidone and hypochlorous acid in deionized water, adding into a vacuum emulsification stirrer, vacuumizing and stirring for 30min; slowly adding a stabilizer and a neutralizer, stirring while adding, and regulating the pH value to be 5; adding the polysaccharide antibiotic compound, stirring at 30deg.C for 20min, slowly adding surfactant, and stirring for 10min to obtain hypochlorous acid disinfectant.
Example 2.
The hypochlorous acid disinfectant of the embodiment comprises the following components in parts by weight: 6 parts of hypochlorous acid, 15 parts of polysaccharide antibiotic compound, 2-6 parts of pyridinium bromide, 9 parts of polyvinylpyrrolidone, 9 parts of stabilizer, 4 parts of neutralizer, 17 parts of surfactant and 80 parts of deionized water.
The concentration of available chlorine in the disinfectant in this example was 800ppm, and the pH value of the entire disinfectant solution was maintained at 6.
The hypochlorous acid preparation method of the embodiment comprises the following steps:
s1, pretreating an anode of an electrolytic cell, adding a carbon nano tube into propylene glycol, performing ultrasonic treatment for 30 minutes, coating an electrode reaction catalyst on the anode, and roasting at 300 ℃ for 30 minutes to finish the treatment;
s2, introducing 0.2wt% of sodium chloride or potassium chloride solution into the cathode chamber and the anode chamber, and connecting with a power supply of an electrolytic tank to electrolyze to obtain hypochlorous acid.
The electrode reaction catalyst of this example was a mixture of platinum dioxide and tin tetrachloride in a mass ratio of 3:1.
The coating amount of the electrode reaction catalyst on the anode of this example was 10g/m 2 。
The preparation method of the polysaccharide antibiotic complex of the embodiment comprises the following steps:
s11, preparing chitosan and antibiotic aqueous solution, wherein the molar ratio of chitosan to antibiotic to deionized water is 1:5:15, adding 30% of cyano sodium borohydride by mass of antibiotics, stirring at room temperature in a dark place, and reacting at 100 ℃ for 12 hours;
s12, transferring the aqueous solution obtained in the step S11 into a 3kDa dialysis bag for dialysis for 3d to obtain a dialysate;
s13, dissolving cellulose in deionized water with the mass of 2 times of that of the cellulose, mixing the cellulose aqueous solution and the dialyzate under the stirring condition, and continuously stirring for 3 hours at 40 ℃;
s14, carrying out vacuum freeze drying on the mixed solution obtained in the step S13 for 48 hours at the temperature of 50 ℃ below zero and the vacuum degree of 30Pa, thus obtaining the polysaccharide antibiotic compound.
The dialysis bag of this example had a molecular weight cut-off of 7000.
The chitosan of the embodiment is carboxymethyl chitosan with the deacetylation degree of more than 80 percent;
the cellulose of this example is sodium carboxymethyl cellulose;
the antibiotic of this example is monensin.
The stabilizer of this example is sodium phosphate.
The neutralizing agent of this example was a PBS solution containing 1wt% sodium thiosulfate, 1wt% lecithin, and 2wt% Tween 60.
The surfactant of this example comprises by weight: 8 parts of fatty alcohol polyoxyethylene ether, 7 parts of sodium dodecyl diphenyl ether disulfonate, 4 parts of sodium hexametaphosphate, 12 parts of alkylphenol polyoxyethylene and 10 parts of nonylphenol polyoxyethylene.
The preparation method of the disinfectant of the embodiment comprises the following steps:
dissolving pyridinium bromide, polyvinylpyrrolidone and hypochlorous acid in deionized water, adding into a vacuum emulsification stirrer, vacuumizing and stirring for 30min; slowly adding a stabilizer and a neutralizer, stirring while adding, and regulating the pH value to be 6; adding the polysaccharide antibiotic compound, stirring at 35deg.C for 30min, slowly adding surfactant, and stirring for 20min to obtain hypochlorous acid disinfectant.
Example 3.
The hypochlorous acid disinfectant of the embodiment comprises the following components in parts by weight: 4 parts of hypochlorous acid, 12 parts of polysaccharide antibiotic compound, 3 parts of pyridinium bromide, 7 parts of polyvinylpyrrolidone, 7 parts of stabilizer, 2 parts of neutralizer, 15 parts of surfactant and 70 parts of deionized water.
The concentration of available chlorine in the disinfectant of this example was 600ppm, and the pH of the entire solution of the disinfectant was maintained at 5.5.
The hypochlorous acid preparation method of the embodiment comprises the following steps:
s1, pretreating an anode of an electrolytic cell, adding a carbon nano tube into propylene glycol, performing ultrasonic treatment for 30 minutes, coating an electrode reaction catalyst on the anode, and roasting at 250 ℃ for 30 minutes to finish the treatment;
s2, introducing 0.15wt% of sodium chloride or potassium chloride solution into the cathode chamber and the anode chamber, and connecting with a power supply of an electrolytic tank to electrolyze to obtain hypochlorous acid.
The electrode reaction catalyst of this example was a mixture of platinum dioxide and tin tetrachloride in a mass ratio of 3:1.
The coating amount of the electrode reaction catalyst on the anode of this example was 9g/m 2 。
The preparation method of the polysaccharide antibiotic complex of the embodiment comprises the following steps:
s11, preparing chitosan and antibiotic aqueous solution, wherein the molar ratio of chitosan to antibiotic to deionized water is 1:4:13, adding sodium cyanoborohydride accounting for 25% of the mass of the antibiotic, stirring at room temperature in a dark place, and reacting at 95 ℃ for 10 hours;
s12, transferring the aqueous solution obtained in the step S11 into a 3kDa dialysis bag for dialysis for 2.5d to obtain a dialysate;
s13, dissolving cellulose in deionized water with the mass of 2 times of that of the cellulose, mixing the cellulose aqueous solution and the dialyzate under the stirring condition, and continuously stirring for 2.5 hours at 35 ℃;
s14, carrying out vacuum freeze drying on the mixed solution obtained in the step S13 for 42h, wherein the temperature is-40 ℃ and the vacuum degree is 30Pa, and thus the polysaccharide antibiotic compound is obtained.
The dialysis bag of this example has a molecular weight cut-off of 5000.
The chitosan of the embodiment is carboxymethyl chitosan with the deacetylation degree of more than 80 percent;
the cellulose of this example is hydroxypropyl cellulose;
the antibiotic of this example is La Sha Junsu.
The stabilizer of this example is sodium silicate.
The neutralizing agent of this example was a PBS solution containing 0.8wt% sodium thiosulfate, 0.7wt% lecithin, and 1.5wt% Tween 60.
The surfactant of this example comprises by weight: 5 parts of fatty alcohol polyoxyethylene ether, 5 parts of sodium dodecyl diphenyl ether disulfonate, 2 parts of sodium hexametaphosphate, 10 parts of alkylphenol polyoxyethylene and 8 parts of nonylphenol polyoxyethylene.
The preparation method of the disinfectant of the embodiment comprises the following steps:
dissolving pyridinium bromide, polyvinylpyrrolidone and hypochlorous acid in deionized water, adding into a vacuum emulsification stirrer, vacuumizing and stirring for 30min; slowly adding a stabilizer and a neutralizer, stirring while adding, and regulating the pH value to 5.5; adding the polysaccharide antibiotic compound, stirring at 30deg.C for 25min, slowly adding surfactant, and stirring for 15min to obtain hypochlorous acid disinfectant.
Comparative example 1.
The difference from example 3 is that no polysaccharide antibiotic complex is added.
Comparative example 2.
Unlike example 3, polyvinylpyrrolidone was not added.
Comparative example 3.
Unlike example 3, the pyridinium bromide was replaced with benzalkonium bromide.
Comparative example 4.
Unlike example 3, the electrode catalyst was Raney-Ni.
Comparative example 5.
The difference from example 3 is that the cellulose in the polysaccharide antibiotic complex is replaced with starch and the chitosan is replaced with bovine serum albumin.
Comparative example 6.
The antibiotic which is the polysaccharide antibiotic complex is penicillin, unlike example 3.
Comparative example 7.
Unlike example 3, the polysaccharide antibiotic complex was prepared by the following method:
s11, respectively dissolving chitosan and cellulose in water, respectively adding sodium borohydride accounting for 50% of the mass of the antibiotics, respectively stirring uniformly, then mixing the chitosan aqueous solution and the cellulose aqueous solution, adding the antibiotics, and stirring for 30min at room temperature in a dark place;
s12, transferring the mixed solution obtained in the step S11 into a dialysis bag with the molecular weight cut-off of 15000 for dialysis for 1d to obtain a dialysate;
and S13, carrying out infrared drying on the dialysate obtained in the step S12 to obtain the polysaccharide antibiotic compound.
The chitosan of the embodiment is carboxymethyl chitosan with the deacetylation degree of more than 80 percent;
the cellulose of this example is sodium carboxymethyl cellulose;
the antibiotic of this example is La Sha Junsu.
1. Sterilization test
Experimental strain: coli, staphylococcus aureus, listeria, candida albicans, pseudomonas aeruginosa, and beta-hemolytic streptococcus.
The 12-hour liquid cultures of the above bacteria were divided into 6 groups, each group containing 10 strain culture samples, the test was performed using the sterilizing solutions of examples 1-3 and comparative examples 1-7, respectively, uniformly coated on the surfaces of common plates with sterile swabs, slightly dried, and the drug-sensitive paper sheets having the sterilizing solutions of examples 1-3 and comparative examples 1-7 absorbed therein were held by sterile forceps, spread on the surfaces of the above bacteria-inoculated plates, one plate was placed with 3 drug-sensitive paper sheets, incubated at 35℃for 30 minutes, and the results were observed and recorded.
Sterilization rate= (average number of bacteria of sample before sterilization-average number of bacteria of sample after sterilization)/average number of bacteria of sample before sterilization.
The test results are shown in Table 1:
2. skin penetration test
The Franz diffusion cell system was used as a device for transdermal permeation testing using a phosphate buffer solution containing 0.5% sodium azide, which was maintained at 30℃and stirred at 500rpm during the test. The hypochlorous acid disinfectant solutions of examples 1-3 and comparative examples 1-7 were sprayed on skin samples of mice comprising epidermis layer and dermis layer, and after 5min, the ointment was uniformly applied, and then the skin samples of mice were placed in a Franz diffusion cell system.
Samples were collected and analyzed by HPLC to determine the 24 hour cumulative penetration (μg/cm) of the ointment 2 ) Cumulative permeation (%) relative to the initial content and skin permeation (μg/cm) 2 /h）。
The test results are shown in Table 2:
according to the test, chitosan, cellulose and antibiotic compound are introduced into the disinfectant, so that the disinfectant can kill pathogens, has an antibacterial effect, good biocompatibility and excellent film forming performance, is sprayed on the surface of a severe skin erosion wound when being used for medical disinfection, acts on the pathogens or bacterial cell membranes which are retained in dermis layers of the skin, causes perforation, damages ion channels of the pathogens, and finally leads to autolysis of the thalli to die. The antibacterial and bacteriostatic breathable film can be formed on the surface of the skin, so that the antibacterial and bacteriostatic breathable film has a blocking effect on external bacteria, the irritation of hypochlorous acid to the skin is reduced, the skin permeability of the ointment is increased, and the antibacterial and bacteriostatic breathable film has a promoting effect on the treatment of drug penetration into the dermis of the skin and the auxiliary hypochlorous acid deep sterilization.
The anode of the electrolytic tank for producing hypochlorous acid is coated with a catalyst, so that an uneven honeycomb coating is formed on the surface of the anode, the number of active electrons on the surface of the anode is increased, the electrochemical activity of the anode is improved, and carbon nanotubes provide attachment points for platinum and tin to promote finer grains, so that the hypochlorous acid produced by the electrode under the condition of low energy consumption can release stable high-concentration available chlorine, and the coordination efficiency with polysaccharide antibiotics is higher.
It will be evident to those skilled in the art that the invention is not limited to the details of the foregoing illustrative embodiments, and that the present invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.
Furthermore, it should be understood that although the present disclosure describes embodiments, not every embodiment is provided with a separate embodiment, and that this description is provided for clarity only, and that the disclosure is not limited to the embodiments described in detail below, and that the embodiments described in the examples may be combined as appropriate to form other embodiments that will be apparent to those skilled in the art.
Claims (5)
1. The hypochlorous acid disinfectant is characterized by comprising the following components in parts by weight: 2-6 parts of hypochlorous acid, 10-15 parts of polysaccharide antibiotic compound, 2-6 parts of pyridinium bromide, 5-9 parts of polyvinylpyrrolidone, 4-9 parts of stabilizer, 1-4 parts of neutralizer, 12-17 parts of surfactant and 65-80 parts of deionized water;
the preparation method of the polysaccharide antibiotic compound comprises the following steps:
s11, preparing chitosan and antibiotic aqueous solution, wherein the molar ratio of chitosan to antibiotic to deionized water is (1:3) - (5): 10-15, adding sodium cyanoborohydride accounting for 20-30% of the mass of the antibiotic, stirring at room temperature in a dark place, and reacting at 90-100 ℃ for 8-12 h;
s12, transferring the aqueous solution obtained in the step S11 into a 3kDa dialysis bag for dialysis for 2-3 d to obtain a dialysate;
s13, dissolving cellulose in deionized water with the mass of 2 times that of the cellulose, mixing a cellulose aqueous solution and a dialyzate under a stirring condition, and continuously stirring for 2-3 hours at the temperature of 30-40 ℃;
s14, carrying out vacuum freeze drying on the mixed solution obtained in the step S13 for 36-48 hours at the temperature of minus 30 to minus 50 ℃ and the vacuum degree of 20-30 Pa, thus obtaining the polysaccharide antibiotic compound;
the chitosan is carboxymethyl chitosan with the deacetylation degree of more than 80%; the cellulose is hydroxypropyl cellulose or sodium carboxymethyl cellulose; the antibiotic is one of vancomycin, tetracycline, la Sha Junsu and monensin;
the preparation method of the hypochlorous acid comprises the following steps:
s1, pretreating an anode of an electrolytic cell, adding a carbon nano tube into propylene glycol, performing ultrasonic treatment for 30 minutes, coating an electrode reaction catalyst on the anode, and roasting at 200-300 ℃ for 30 minutes to finish the treatment;
s2, introducing 0.1-0.2wt% of sodium chloride or potassium chloride solution into the cathode chamber and the anode chamber, connecting with a power supply of an electrolytic tank, and electrolyzing to obtain hypochlorous acid;
the electrode reaction catalyst is a mixture of platinum dioxide and tin tetrachloride in a mass ratio of 3:1;
the stabilizer comprises one or more of disodium ethylenediamine tetraacetate, sodium silicate and sodium phosphate;
the neutralizer is PBS solution containing 0.5-1wt% of sodium thiosulfate, 0.5-1wt% of lecithin and 1-2wt% of Tween 60.
2. The hypochlorous acid disinfectant as set forth in claim 1, wherein the disinfectant comprises, in parts by weight: 3-5 parts of hypochlorous acid, 11-14 parts of polysaccharide antibiotic compound, 2-4 parts of pyridinium bromide, 6-8 parts of polyvinylpyrrolidone, 6-8 parts of stabilizer, 1-3 parts of neutralizer, 13-16 parts of surfactant and 68-73 parts of deionized water.
3. The hypochlorous acid disinfectant as set forth in claim 1, wherein the disinfectant comprises, in parts by weight: 4 parts of hypochlorous acid, 12 parts of polysaccharide antibiotic compound, 3 parts of pyridinium bromide, 7 parts of polyvinylpyrrolidone, 7 parts of stabilizer, 2 parts of neutralizer, 15 parts of surfactant and 70 parts of deionized water.
4. A hypochlorous acid sanitizing liquid as set forth in claim 1 wherein said surfactant comprises by weight: 2-8 parts of fatty alcohol polyoxyethylene ether, 3-7 parts of sodium dodecyl diphenyl ether disulfonate, 1-4 parts of sodium hexametaphosphate, 8-12 parts of alkylphenol polyoxyethylene and 5-10 parts of nonylphenol polyoxyethylene.
5. The hypochlorous acid disinfectant as set forth in claim 1, wherein the disinfectant is prepared by the steps of:
dissolving pyridinium bromide, polyvinylpyrrolidone and hypochlorous acid in deionized water, adding into a vacuum emulsification stirrer, vacuumizing and stirring for 30min; slowly adding a stabilizer and a neutralizer, stirring while adding, and adjusting the pH value to 5-6; and adding the polysaccharide antibiotic compound, stirring for 20-30 min at 30-35 ℃, slowly adding the surfactant, and stirring for 10-20 min to obtain the hypochlorous acid disinfectant.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310736606.0A CN116473997B (en) | 2023-06-21 | 2023-06-21 | Hypochlorous acid disinfectant and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310736606.0A CN116473997B (en) | 2023-06-21 | 2023-06-21 | Hypochlorous acid disinfectant and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116473997A CN116473997A (en) | 2023-07-25 |
| CN116473997B true CN116473997B (en) | 2023-11-24 |
Family
ID=87212189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310736606.0A Active CN116473997B (en) | 2023-06-21 | 2023-06-21 | Hypochlorous acid disinfectant and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116473997B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000154109A (en) * | 1998-03-12 | 2000-06-06 | Oji Paper Co Ltd | Natural substance-originated sterilizing agent |
| CN111188052A (en) * | 2020-02-27 | 2020-05-22 | 上海广锋生物科技有限公司 | Preparation method of high-performance hypochlorous acid |
| CN111990411A (en) * | 2020-09-10 | 2020-11-27 | 安徽理工大学 | Composite intermediate-effect disinfectant and preparation process thereof |
| CN112042667A (en) * | 2020-08-21 | 2020-12-08 | 山东知能环保科技有限公司 | Stable hypochlorous acid disinfectant and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100203125A1 (en) * | 2004-02-16 | 2010-08-12 | Sanjeev Khandelwal | Synergistic antibacterial formulation and a method of making the same |
-
2023
- 2023-06-21 CN CN202310736606.0A patent/CN116473997B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000154109A (en) * | 1998-03-12 | 2000-06-06 | Oji Paper Co Ltd | Natural substance-originated sterilizing agent |
| CN111188052A (en) * | 2020-02-27 | 2020-05-22 | 上海广锋生物科技有限公司 | Preparation method of high-performance hypochlorous acid |
| CN112042667A (en) * | 2020-08-21 | 2020-12-08 | 山东知能环保科技有限公司 | Stable hypochlorous acid disinfectant and preparation method thereof |
| CN111990411A (en) * | 2020-09-10 | 2020-11-27 | 安徽理工大学 | Composite intermediate-effect disinfectant and preparation process thereof |
Non-Patent Citations (1)
| Title |
|---|
| 壳聚糖抗菌性能研究进展;俞娟等;《林业工程学报》;第3卷(第5期);第20-27页摘要、1-3部分 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116473997A (en) | 2023-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101278896B (en) | Chitosan nano silver gel agent and uses thereof | |
| CH701627B1 (en) | Process for the preparation of a composition of hypochlorous acid and its uses. | |
| JP2007517064A5 (en) | ||
| EP1214081A2 (en) | Superoxidized water based on hypochlorous acid for the treatment of wounds | |
| EP1948200B1 (en) | Wound-healing composition | |
| CN110150316A (en) | A kind of preparation method of nano silver/subchloride composite bactericidal liquid | |
| JP2012516893A (en) | Treatment of non-oral biological tissues with chlorine dioxide | |
| CN101163492B (en) | Method of treating skin ulcers using oxidative reductive potential water solution | |
| US10617715B2 (en) | Methods of treating or preventing biofilm associated infections with free available chlorine free available chlorine water | |
| CN111617103A (en) | Silver ion graphene oxide-containing antibacterial and disinfectant protective cleaning solution | |
| CN116473997B (en) | Hypochlorous acid disinfectant and preparation method thereof | |
| CN110801530A (en) | Aseptic liquid dressing and its preparing process | |
| CN113040135A (en) | Nano-silver composite hydrosol disinfectant and preparation method thereof | |
| CN115770195A (en) | Stable acne-removing composition and preparation method thereof | |
| CN101972271B (en) | Chlorine dioxide mucous membrane gel and preparation method thereof | |
| CN109526982A (en) | The antimicrobial solutions of low pH a kind of and its application | |
| CN113967192A (en) | Pharmaceutical composition for accelerating wound healing, preparation method and application thereof | |
| JP2011502143A (en) | Bactericidal composition comprising peracid and acetylsalicylic acid | |
| CN109876007B (en) | Ozone antibacterial and disinfecting gel and preparation method thereof | |
| CN112897194A (en) | Production method of degradable hypochlorous acid disinfection wet tissue | |
| CN101972272A (en) | Chlorine dioxide skin gel and preparation method thereof | |
| CN114917267B (en) | Iodine-containing disinfectant for skin and preparation method thereof | |
| CN114504647B (en) | Hydrogel and preparation method and application thereof | |
| CN214735499U (en) | Film with antibacterial, bactericidal and disinfecting functions | |
| CN220548525U (en) | Nano composite antibacterial plastic master batch |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |